Citius Pharmaceuticals, Inc. (CTXR)
2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Stock-based compensation general and administrative | 2,719,674 | 2,702,031 | 2,524,824 | 3,061,763 |
| Research and development | 1,621,325 | 3,766,525 | 2,127,038 | 2,763,865 |
| General and administrative | 4,447,008 | 4,792,122 | 5,387,752 | 4,808,551 |
| Total operating expenses | 8,788,007 | 11,260,678 | 10,039,614 | 10,634,179 |
| Operating loss | -8,788,007 | -11,260,678 | -10,039,614 | -10,634,179 |
| Interest income | 20,637 | 13,413 | 22,608 | 204,843 |
| Interest expense | 172,262 | - | - | - |
| Gain on sale of new jersey net operating losses | - | - | - | - |
| Total other income (expense) | -151,625 | 13,413 | 22,608 | 204,843 |
| Loss before income taxes | -8,939,632 | -11,247,265 | -10,017,006 | -10,429,336 |
| Income tax expense | 264,240 | 264,240 | 264,240 | 144,000 |
| Net loss | -9,203,872 | -11,511,505 | -10,281,246 | - |
| Net loss attributable to non-controlling interest | -414,000 | -595,000 | -513,000 | - |
| Deemed dividend on warrant extension | - | - | - | 321,559 |
| Net loss | - | - | - | -10,573,336 |
| Net loss applicable to common stockholders | -8,789,872 | -10,916,505 | -9,768,246 | -10,894,895 |
| Basic (in shares) | 11,006,896 | 8,581,207 | 7,492,460 | 173,856,960 |
| Diluted (in shares) | 11,006,896 | 8,581,207 | 7,492,460 | 173,856,960 |
| Net loss per share - basic (in dollars per share) | -0.8 | -1.27 | -1.3 | - |
| Net loss per share - diluted (in dollars per share) | -0.8 | -1.27 | -1.3 | - |